Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meet...
November 09 2020 - 8:00AM
Business Wire
Incyte (Nasdaq:INCY) today announced that abstracts highlighting
data from its oncology portfolio will be presented at the Society
for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually
from November 11-14, 2020.
“We are excited to join the oncology community at the SITC 35th
anniversary annual meeting and look forward to sharing data from
our immuno-oncology portfolio,” said Lance Leopold, Group Vice
President, Immuno-Oncology, Incyte. “In particular, initial
translational data from the ongoing clinical trial support further
development of our orally administered PD-L1 inhibitor INCB86550 —
a novel small-molecule discovered at Incyte.”
E-Poster Presentations:
Pharmacodynamic Biomarkers Demonstrate T-Cell Activation in
Patients Treated with the Oral PD-L1 Inhibitor INCB086550 in a
Phase 1 Clinical Trial [Poster #419]
Retrospective Pooled Analysis of Epacadostat Clinical Studies
Identifies Doses Required for Maximal Pharmacodynamic Effect in
Anti-PD-1 Combination Studies [Poster #28]
MCLA-145 (CD137xPD-L1): A Potent CD137 Agonist and Immune
Checkpoint Inhibitor That Does Not Show Signs of Peripheral
Toxicity [Poster #814]1
MCLA-145 is a Bispecific IgG1 Antibody that Inhibits
PD-1/PD-L1 Signaling While Simultaneously Activating CD137
Signaling on T Cells [Poster #820]1
A Phase 1 Study of Retifanlimab (INCMGA00012), a PD-1
Inhibitor, in Patients with Advanced Solid Tumors: Preliminary
Results in Recurrent MSI-High or dMMR Endometrial Cancer
(POD1UM-101) [Poster #268]
A Phase 2 Umbrella Study of Retifanlimab (INCMGA00012) Alone
or in Combination with Other Therapies in Patients with Advanced or
Metastatic Endometrial Cancer (POD1UM-204, GOG 3038,
ENGOT-en12/NOGGO) [Trial in Progress; Poster #348]2
All posters will be on display from Monday, November 9, 2020
until the virtual poster hall closes on December 31, 2020.
Abstracts are available on the SITC 2020 website at
https://www.sitcancer.org/2020.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical
company focused on finding solutions for serious unmet medical
needs through the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte,
please visit Incyte.com and follow @Incyte.
1Merus-sponsored; 2In collaboration with the Gynecologic
Oncology Group and the European Network for Gynecological
Oncological Trial (ENGOT) groups.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201109005088/en/
Incyte Media Catalina
Loveman +1 302 498 6171 cloveman@incyte.com Nupur Patel, PharmD +1
302 498 5822 npatel@incyte.com
Investors Michael Booth, DPhil +1 302 498 5914
mbooth@incyte.com Christine Chiou +1 302 274 4773
cchiou@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024